at6

AT6 is a PROTAC AT1 analog which is a highly selective bromodomain (Brd4) degrader.

KAT681 is a liver selective thyromimetic.

KAT6-IN-2 is a potent inhibitor of KAT6, showing promise for use in cancer research.

KAT6A-IN-2 (compound 7) is an inhibitor of KAT6A.

KAT6A-IN-1 (compound 5) is an inhibitor of KAT6A.

KAT6-IN-3 (compound 10) competitively targets and binds to KAT6A and KAT6B.

KAT6A/KAT7-IN-3 (Example 191) is an inhibitor of KAT6A and KAT7. It exhibits an IC50 of 10-50 nM for KAT6A and 1 nM or less for KAT7. This compound inhibits acetylation of H3K14 and H3K23 and suppresses tumor cell proliferation, with an IC50 of 2-5 μM for CAMA-1. KAT6A/KAT7-IN-3 is applicable in cancer research.

STAT6-IN-7 (Compound 178) is a STAT6 inhibitor with an IC50 of 0.28 μM for inhibiting the binding of human STAT6/pIL-4Rα. It is utilized in research related to inflammation and allergic diseases.

KAT6A/KAT7-IN-2 (Example 177) is an inhibitor targeting KAT6A and KAT7, with an IC50 of 1 nM or less for both enzymes. It inhibits acetylation of H3K14 and H3K23 and also suppresses tumor cell proliferation, demonstrating an IC50 of 100 nM or less for CAMA-1 cells. This compound is applicable in cancer research.

KAT6A/KAT7-IN-4 (Example 230) is an inhibitor targeting KAT6A and KAT7, with an IC50 of less than or equal to 1 nM for both enzymes. It inhibits acetylation of H3K14 and H3K23 and suppresses tumor cell proliferation, specifically showing an IC50 of less than or equal to 100 nM for CAMA-1. This compound is useful in cancer research.

KAT6A/KAT7-IN-1 (Example 113) is an inhibitor targeting both KAT6A and KAT7. It shows an IC50 for KAT6A of greater than 1 nM and up to 10 nM, while for KAT7, the IC50 is 1 nM or less. This compound suppresses acetylation of H3K14 and H3K23. Additionally, KAT6A/KAT7-IN-1 inhibits tumor cell proliferation with an IC50 for CAMA-1 of more than 2 μM but no greater than 5 μM. It is applicable in tumor research.

NAT6-297775 is a SHP2 inhibitor with IC50 =2.47uM.

STAT6-IN-1, a STAT6 inhibitor, exhibits high affinity for the SH2 domain of STAT6 (IC 50 = 0.028 µM), making it suitable for research on allergic lung disease, allergic rhinitis, chronic obstructive pulmonary disease, or cancer.

KAT6-IN-1 (compound E) is a selective, orally available inhibitor of histone acetyltransferases KAT6A and KAT6B, exhibiting antitumour activity for cancer research.

STAT6-IN-2 (Comp R-84) is a STAT6 inhibitor that effectively reduces the secretion of the chemokine eotaxin-3, which induces eosinophil infiltration. This compound is valuable for studying immune diseases [1].

STAT6-IN-3 (Compound 18a) is an inhibitor of STAT6, targeting the Src Homology 2 (SH2) domain with an IC50 value of 44 nM. It is used in research on inflammatory disorders, such as asthma [1].

STAT6-IN-5 (example 84) is an inhibitor of STAT6 (IC50 = 0.24 μM), applicable for investigating inflammation and allergies such as atopic dermatitis.

STAT6-IN-4 (compound 78) is a STAT6 inhibitor with an IC₅₀ of 0.34 μM, suitable for investigating inflammatory and allergic diseases.

ESAT6 Epitope is a known CD4+ T cell epitope within the Early Secretory Antigenic Target 6 (ESAT6), demonstrating nanoscale affinity (IC50=180 nM) for Major Histocompatibility Complex MHC class I. Additionally, ESAT6 Epitope can enhance the anti-tuberculosis cellular immunity initiated by the Bacille Calmette-Guérin vaccine.

BAT6026 is a human monoclonal antibody (mAb) that targets TNFRSF4/OX40/CD134. It notably reduces Treg cells within tumors and increases CD8+ T cells.

SD-436 is a selective and highly efficient STAT3 PROTAC degrader (DC50 = 0.5 μM), with an IC50 of 19 nM for STAT3, significantly higher than for STAT1/4/5/6. SD-436 depletes STAT3 and induces tumour regression in mouse leukaemia and lymphoma xenograft models.

AT-61 is a nonnucleoside analogue inhibitor of hepatitis B virus (HBV) replication.

AS1517499 is a blood-brain barrier permeable inhibitor of STAT6 phosphorylation (IC50= 21 nM).

WM-1119 is a highly potent, selective KAT6A/B inhibitor